Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cellectis Trading Up 12.0 %

NASDAQ CLLS opened at $3.35 on Friday. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.50 and a quick ratio of 1.50. The business has a 50 day simple moving average of $2.62 and a 200 day simple moving average of $2.72. The stock has a market capitalization of $186.19 million, a P/E ratio of -1.95 and a beta of 3.08.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. Cellectis had a negative net margin of 1,087.66% and a negative return on equity of 99.88%. The company had revenue of $1.99 million during the quarter. Research analysts expect that Cellectis will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. increased its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.